Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Beats Revenue Estimates

Group 1 - Biorestorative Therapies, Inc. reported a quarterly loss of $0.3 per share, which was better than the Zacks Consensus Estimate of a loss of $0.41, representing an earnings surprise of +26.83% [1] - The company posted revenues of $0.3 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 51.50%, compared to revenues of $0.09 million a year ago [2] - Over the last four quarters, Biorestorative Therapies has surpassed consensus EPS estimates three times, but has only topped consensus revenue estimates once [2] Group 2 - The stock has underperformed the market, losing about 1.4% since the beginning of the year, while the S&P 500 has gained 8.4% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.43 on $0.3 million in revenues, and -$1.76 on $0.93 million in revenues for the current fiscal year [7] Group 3 - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stocks in this sector [8] - The estimate revisions trend for Biorestorative Therapies was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market [6]